• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Mizuho initiated coverage on CRISPR Therapeutics with a new price target

    9/27/23 8:04:42 AM ET
    $CRSP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $CRSP alert in real time by email
    Mizuho initiated coverage of CRISPR Therapeutics with a rating of Buy and set a new price target of $82.00
    Get the next $CRSP alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CRSP

    DatePrice TargetRatingAnalyst
    2/14/2025$60.00 → $99.00In-line → Outperform
    Evercore ISI
    2/12/2025$35.00Sell → Hold
    TD Cowen
    2/3/2025$65.00Buy
    H.C. Wainwright
    8/6/2024$88.00 → $84.00Buy
    Needham
    8/2/2024$90.00Buy
    Rodman & Renshaw
    6/28/2024Neutral
    Guggenheim
    2/15/2024Peer Perform
    Wolfe Research
    12/11/2023$30.00Market Perform → Underperform
    TD Cowen
    More analyst ratings

    $CRSP
    SEC Filings

    See more
    • CRISPR Therapeutics AG filed SEC Form 8-K: Other Events

      8-K - CRISPR Therapeutics AG (0001674416) (Filer)

      6/26/25 7:08:02 AM ET
      $CRSP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • CRISPR Therapeutics AG filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - CRISPR Therapeutics AG (0001674416) (Filer)

      6/9/25 4:33:09 PM ET
      $CRSP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 424B5 filed by CRISPR Therapeutics AG

      424B5 - CRISPR Therapeutics AG (0001674416) (Filer)

      5/19/25 5:10:45 PM ET
      $CRSP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CRSP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • CRISPR Therapeutics upgraded by Evercore ISI with a new price target

      Evercore ISI upgraded CRISPR Therapeutics from In-line to Outperform and set a new price target of $99.00 from $60.00 previously

      2/14/25 8:06:15 AM ET
      $CRSP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • CRISPR Therapeutics upgraded by TD Cowen with a new price target

      TD Cowen upgraded CRISPR Therapeutics from Sell to Hold and set a new price target of $35.00

      2/12/25 7:01:19 AM ET
      $CRSP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • H.C. Wainwright initiated coverage on CRISPR Therapeutics with a new price target

      H.C. Wainwright initiated coverage of CRISPR Therapeutics with a rating of Buy and set a new price target of $65.00

      2/3/25 7:05:27 AM ET
      $CRSP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care